Recent News About Dechert Llp
View More
-
A bill passed in California setting gender quotas on the boards of public companies could generate significant legal challenges, which likely would need to be resolved before other states move to copy it, an attorney following the legislation believes.
-
A federal judge has put a hold on any further proceedings in the massive, years-long nationwide legal action against Abbvie and other makers of so-called testosterone replacement therapy drugs, saying he wants to give both sides time to complete a potential settlement drug to permanently end the litigation.
-
While noting the plaintiffs had presented statements which could indicate price-fixing activity, a federal appeals panel has refused to melt down a lower court’s decision to slice up a potentially massive class action lawsuit accusing U.S. steelmakers of conspiring to jack up prices for raw steel.
-
A federal judge has knocked down a $140 million verdict against pharmaceutical maker AbbVie, ordering a new trial over a man’s claims AbbVie’s Androgel testosterone replacement therapy drug caused him to suffer a heart attack.
-
A federal jury has handed a win to North Chicago-based drugmaker Abbvie, as it continues to seek to fend off a mass of legal claims accusing the company’s testosterone replacement therapy drug, Androgel, of causing heart attacks and other cardiovascular conditions.
-
A federal judge has denied a request to dismiss a class-action suit against Allstate for allegedly placing unsolicited sales calls to customers’ cell phones, even though the lead plaintiff received only one such phone call.
-
North Chicago-based drugmaker AbbVie is resisting what it is calling a jury's “confused and inconsistent” $3.2 million verdict, after the company lost a second trial in Chicago federal court – one in which it was ordered to pay $147 million less than the first trial – over a man’s claims AbbVie allegedly failed to warn its product AndroGel could bring on a heart attack.
-
About three months after a federal judge threw out a jury’s $150 million verdict and ordered a new trial in the case, a new jury in Chicago has ordered drugmaker Abbvie to pay about $3.2 million to a man who claimed Abbvie’s drug Androgel had caused him to suffer a heart attack.
-
After split verdicts in two prior trials over alleged harmful side effects and alleged misleading marketing of its testosterone replacement drug led to questionable verdicts worth more than $140 million each, drugmaker Abbvie has scored a clean win in the latest jury review of a plaintiff’s claims over the promotion and health impacts of Androgel.
-
Saying the jury’s findings were too conflicting and inconsistent to unravel in a post-trial motion, a Chicago federal judge has instead ordered a new trial, tossing out that jury’s verdict ordering drugmaker AbbVie to pay $150 million to a man who claimed AbbVie’s promotion of its testosterone therapy drug, Androgel, led his doctor to prescribe it to him, allegedly later resulting in a heart attack.
-
North Chicago-based drugmaker AbbVie has asked a federal judge to toss out a $140 million verdict against it for allegedly mismarketing its testosterone replacement therapy drug, Androgel. And in the view of a Chicago attorney whose practice focuses on Supreme Court and appellate cases, as well as class actions, there is "no chance" that judgment will be allowed to stand.
-
North Chicago-based drug company AbbVie is urging a federal judge to trash a verdict ordering it to cough up $140 million, because its testosterone therapy drug AndroGel contributed to a man's heart attack, contending it has no liability because AndroGel was approved by the FDA.
-
Drugmaker Abbvie has suffered another big loss in court, as a Chicago federal jury has ordered the North Chicago-based pharmaceutical company to pay out $140 million to another man who claimed he had suffered a heart attack as a result of taking Abbvie’s testosterone therapy drug, Androgel.
-
A federal jury has ordered drugmaker AbbVie to pay $150 million in damages for allegedly falsely marketing the benefits of its Androgel testosterone therapy drug, even though the jury did not hold the company liable for a heart attack suffered by a man taking the drug.
-
A Chicago federal jury shocked many observers by ordering drugmaker GlaxoSmithKline to pay $3 million to the widow of lawyer Stewart Dolin, who committed suicide in 2010 after taking a generic version of GSK's antidepressant Paxil. But legal observers believe the decision may have a short shelf life, as it could defy decades of case law on the concept of innovator liability.
-
A Chicago federal judge has dismissed several. but not all of the claims against the maker of a testosterone boosting drug, advanced by several plaintiffs chosen as bellwethers in a class-action lawsuit brought by more than 2,000 plaintiffs from around the U.S. against multiple drug manufacturers, including Besins, AbbVie, Eli Lilly and GlaxoSmithKline.
-
A group of steel makers, led by Chicago-based ArcelorMittal USA, have beaten down a class-action antitrust lawsuit filed by more than a dozen consumers, who alleged the companies schemed to raise prices for goods made with steel, by pointing out the consumers were too far down the distribution line from the steel manufacturers to claim losses.
-
A Chicago federal judge has chopped a few counts from a huge putative class-action suit – based on laws of various states, including Illinois – accusing the maker of the prescription pain killer Opana of improperly keeping the price of its product high by paying off another pharmaceutical company to delay the release of a generic version of the drug.
-
A Chicago federal judge has kicked drug retailers Walgreen and Rite Aid from an antitrust lawsuit against the maker of prescription pain killer Opana, saying the retailers must provide hard dollar figures to back up their allegations that the drugmaker improperly paid off another pharmaceutical company to delay the release of the generic version of its pain killer, and keep the price of its name brand drug high.
-
A Cook County judge has refused to allow Wade D. Miquelon, former chief financial officer at Walgreens, to proceed with much of his defamation and breach of contract lawsuit against his former employer, in which he alleged Walgreens executives lied to investors and the press about why he had departed the company in 2014. Now, Miquelon has asked the judge for permission to amend his complaint again.
